儿童脂质体两性霉素B预防性用药的系统综述
该系统综述检索EMBASE、Medline、Web of Science和Cochrane数据库至2023年12月7日,纳入20项研究共2015例患儿,评估脂质体两性霉素B(LAmB)预防侵袭性真菌病(IFD)的突破性感染比例与毒性。突破性IFD发生率为7.2%(49/676),低钾血症23.2%(125/538),肝功能异常15.0%(49/327),因毒性停药6.0%(30/503)。因人群、给药方案和研究设计异质性,无法得出疗效或最优方案结论。
要点
- 儿童预防性LAmB的突破性IFD发生率为7.2%(49/676)。
- 最常见不良反应为低钾血症23.2%(125/538)和肝功能异常15.0%(49/327)。
- 因毒性停药发生率为6.0%(30/503)。
核心结论
- 尽管预防性LAmB广泛使用,本系统综述提示支持其使用的儿科数据匮乏。
- 人群、给药方案和研究设计的异质性妨碍就其疗效或某一给药方案的优越性得出结论。
- 明确需要进一步高质量稳健的临床数据和针对性药代动力学研究。
研究设计与样本
- 系统综述,遵循PRISMA指南,检索EMBASE、Medline、Web of Science和Cochrane数据库至2023年12月7日。
- 纳入20项研究:3项临床试验、12项队列研究、2项时点患病率调查和3项药代动力学(PK)研究,共2015例患者。
- 717例提供了个体患者数据。
主要发现
- 突破性IFD发生于7.2%(49/676)。
- 低钾血症发生于23.2%(125/538),肝功能检查异常发生于15.0%(49/327)。
- 因毒性停药发生于6.0%(30/503)。
- 4项研究报告PK数据:2项检测LAmB血清水平,1项分析脑脊液水平,另1项分析腹膜水平。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liposomal amphotericin B (LAmB) is widely used for prophylaxis in paediatric patients at high risk of invasive fungal diseases (IFD) but its use is off-label and there is significant variability in dosage and frequency. This systematic review was conducted to evaluate the published data on prophylactic LAmB use in the paediatric population and to present the reported proportions of breakthrough IFD and the associated toxicity profile. METHODS: EMBASE, Medline, Web of Science and the Cochrane Database were systematically searched for primary research reporting on the use of LAmB as prophylaxis for IFD in the paediatric population up to 7 December 2023, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Twenty studies, comprising three clinical trials, 12 cohort studies, two point-prevalence surveys and three pharmacokinetic (PK) studies, with 2015 patients were included. A total of 717 cases presented individual patient data. Breakthrough IFD occurred in 7.2% (49/676). The most recognized side effects were hypokalaemia in 23.2% (125/538) and derangement of liver function tests in 15.0% (49/327). Discontinuation due to toxicity occurred in 6.0% (30/503) of patients. Of the four studies reporting PK data, two examined serum levels of LAmB, one analysed CSF levels and the remaining study peritoneal levels. CONCLUSIONS: Despite widespread use of prophylactic LAmB, this systematic review highlights the paucity of paediatric data supporting its use. The heterogeneity observed in populations, dosing regimens and study design prevents conclusions being reached on its efficacy or the superiority of one dosing regimen. Overall, there is a clear need for further high-quality robust clinical data and targeted PK studies.
引用
- Thorley EV, Hatch J, Li M, et al. Liposomal amphotericin B prophylaxis in paediatrics: a systematic review. J Antimicrob Chemother. 2025. PMID: 40493030. doi:10.1093/jac/dkaf171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。